Advanced glycation end products in age-related macular degeneration

Archives of Ophthalmology

Volumn 116, Issue 12, 1998, Pages 1629-1632

  Ishibashi, Tatsuro ^a   Murata, Toshinori ^c   Hangai, Masanori ^c   Nagai, Ryoji ^b   Horiuchi, Seikoh ^b   Lopez, Pedro F ^c,d   Hinton, David R ^c   Ryan, Stephen J ^a,c,e  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Center for Excellence in Eye Care Florida   (United States)

^e DOHENY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CYTOKERATIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUSEN; EXCISION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

EID: 0032408085     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.116.12.1629     Document Type: Article

References (24)

1. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest. 1990;85:380-384.
2. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med. 1995;46:223-234.
3. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101: 1219-1224.
4. Yamagishi Si, Yonekura H, Yamamoto Y, et al. Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem. 1997;272:8723-8730.
5. Horiuchi S, Araki N, Morino Y. Immunochemical approach to characterize advanced glycation end products of the Maillard reaction: evidence for the presence of a common structure. J Biol Chem. 1991;266:7329-7332.
6. Coffey AJ, Brownstein S. The prevalence of macular drusen in postmortem eyes. Am J Ophthalmol. 1986;102:164-171.
7. Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-related macular degeneration. Eye. 1994;8:269-283.
8. ∈-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 1995;34:10872-10878.
9. ∈-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry. 1996;35:8075-8083.
10. Lambert HM, Capone AJ, Aaberg TM, Sternberg PJ, Mandell BA, Lopez PF. Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1992;113:257-262.
11. Handa JT, Matsunaga A, Aotaki-Keen A, Lutty GA, Hjelmeland LM. Immunohistochemical evidence for deposition of advanced glycation endproducts (AGEs) in Bruch's membrane and choroid with age. Invest Ophthalmol Vis Sci. 1998; 39:S370.
12. Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1997;235:159-167.
13. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
14. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
15. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong P. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997; 81:154-162.
16. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
17. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13:37-50.
18. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, de Jong PT. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35:2857-2864.
19. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997; 40:764-769.
20. Makino H, Shikata K, Kushiro M, et al. Roles of advanced glycation end-products in the progression of diabetic nephropathy. Nephrol Dial Transplant. 1996;5:76-80.
21. Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest. 1997;99:1016-1027.
22. Handa JT, Reiser KM, Matsunaga H, Hjelmeland LM. The advanced glycation end-product pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells. Exp Eye Res. 1998;66:411-419.
23. ∈-(carboxymethyl) lysine formation from Amadori product. Biochem Biophys Res Commun. 1997; 234:167-172.
24. Ryan SJ, Stout JT, Dugel PU. Subretinal neovascularization. In: Ryan SJ, ed. Retina. St Louis, Mo: Mosby-Year Book Inc; 1994:1027-1047.